A specific inhibitor of plasminogen activator inhibitor-1 suppresses rat autoimmune myocarditis

Expert Opinion on Therapeutic Targets

Volumn 12, Issue 11, 2008, Pages 1313-1320

  Suzuki, Jun Ichi ^a,b   Ogawa, Masahito ^b   Muto, Susumu ^c   Itai, Akiko ^c   Isobe, Mitsuaki ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c Inst of Medicinal Molecular Design   (Japan)

Author keywords

Animal models; IMD 1622; Myocarditis; Plasminogen activator inhibitor 1; Rats

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; IMD 1622; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MYOSIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE MYOCARDITIS; CELL INFILTRATION; CONTROLLED STUDY; DISEASE MODEL; DRUG MECHANISM; DRUG RESPONSE; ECHOCARDIOGRAPHY; GENE EXPRESSION REGULATION; HEART FUNCTION; HEART LEFT VENTRICLE CONTRACTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART WEIGHT; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LEWIS RAT; MALE; MYOCARDITIS; NONHUMAN; RAT;

ANIMALS; CYTOKINES; FIBROSIS; GENE EXPRESSION REGULATION; INFLAMMATION; MALE; MYOCARDITIS; MYOCARDIUM; ORGAN SIZE; PERSONAL SPACE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; RATS, INBRED LEW; RNA, MESSENGER; THIAZOLIDINEDIONES;

EID: 56249147813     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.12.11.1313     Document Type: Article

References (33)

1. Haas GJ. Etiology, evaluation, and management of acute myocarditis. Cardiol Rev 2001;9:88-95
2. Oakley CM. Myocarditis, pericarditis and other pericardial diseases. Heart 2000;84:449-54
3. Batra AS, Liewis AB. Acute myocarditis. Curr Opin Pediatr 2001;13:234-9
4. Zee-Cheng CS, Tsai CC, Palmer DC, et al. High incidence of myocarditis by endomyocardial biopsy in patients with idiopathic congestive cardiomyopathy. J Am Coll Cardiol 1984;3:63-70
5. Parrillo JE, Aretz HT, Palacios I, et al. The results of transvenous endomyocardial biopsy can frequently be used to diagnose myocardial diseases in patients with idiopathic heart failure: endomyocardial biopsies in 100 consecutive patients revealed a substantial incidence of myocarditis. Circulation 1984;69:93-101
6. Frustaci A, Chimenti C, Calabrese F, et al. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 2003;107:857-63
7. Liu PP, Mason JW. Advances in the understanding of myocarditis. Circulation 2001;104:1076-82
8. Kühl U, Pauschinger M, Schwimmbeck PL, et al. Interferon-β treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 2003;107:2793-8
9. Matsumoto Y, Jee Y, Sugisaki M. Successful TCR-based immunotherapy for autoimmune myocarditis with DNA vaccines after rapid identification of pathogenic TCR. J Immunol 2000;164:2248-54
10. Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation 2001;104:39-45
11. East E, Baker D, Pryce C, et al. A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis. Am J Pathol 2005;167:545-54
12. Suzuki J, Ogawa M, Muto S, et al. A critical role of plasminogen activator inhibitor-1 in the development of neointimal hyperplasia after arterial injury. Expert Opin Ther Targets 2008;12:783-94
13. Suzuki J, Ogawa M, Futamatsu H, et al. Tea catechins improve left ventricular dysfunction, suppress myocardial inflammation and fibrosis, and alter cytokine expression in rat autoimmune myocarditis. Eur J Heart Fail 2007;9:152-9
14. Suzuki J, Ogawa M, Futamatsu H, et al. A cyclooxygenase-2 inhibitor alters Th1/Th2 cytokine balance and suppresses autoimmune myocarditis in rats. J Mol Cell Cardiol 2006;40:688-95
15. Futamatsu H, Suzuki J, Koga N, et al. A CCR1 antagonist prevents the development of experimental autoimmune myocarditis in association with T cell inactivation. J Mol Cell Cardiol 2006;40:853-61
16. Futamatsu H, Suzuki J, Mizuno S, et al. Hepatocyte growth factor ameliorates the progression of experimental autoimmune myocarditis: a potential role for induction of T helper 2 cytokines. Circ Res 2005;96:823-30
17. Azuma RW, Suzuki J, Ogawa M, et al. HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation. Cardiovasc Res 2004;64:412-20
18. Kitabayashi H, Isobe M, Watanabe N, et al. FTY 720 prevents development of experimental autoimmune myocarditis through reduction of circulating lymphocytes. J Cardiovasc Pharmacol 2000;35:410-6
19. Yokoseki O, Suzuki J, Kitabayashi H, et al. cis element decoy against nuclear factor-κB attenuates development of experimental autoimmune myocarditis in rats. Circ Res 2001;89:899-906
20. Futamatsu H, Suzuki J, Kosuge H, et al. Attenuation of experimental autoimmune myocarditis by blocking activated T cells through inducible costimulatory molecule pathway. Cardiovasc Res 2003;59:95-104
21. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978;58:1072-83
22. Litwin SE, Katz SE, Morgan JP, Douglas PS. Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation 1994;89:345-54
23. Seko Y, Takahashi N, Azuma M, et al. Effects of in vivo administration of anti-B7-1/B7-2 monoclonal antibodies on murine acute myocarditis caused by coxsackie virus B3. Circ Res 1998;82:613-8
24. Suzuki J, Cole SE, Batirel S, et al. Tumor necrosis factor receptor-1 and -2 double deficiency reduces graft arterial disease in murtne cardiac allografts. Am J Transplant 2003;3:968-76
25. Strauss BH, Lau HK, Bowman KA, et al. Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis. Circulation 1999;100:1616-22
26. Nordt TK, Peter K, Ruef J, et al. Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease. Thromb Haemost 1999;82:14-8
27. Levi M, Van Der Poll T. Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med 2005;15:254-9
28. Rijneveld AW, Florquin S, Bresser P, et al. Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumonia. Blood 2003;103:934-9
29. Chazaud B, Ricoux R, Christov C, et al. Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations. Am J Pathol 2002;160:237-46
30. Duffy MJ, Duggan C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem 2004;37:541-8
31. Pauschinger M, Chandrasekharan K, Schultheiss HP. Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-TIMP system. Heart Fail Rev 2004;9:21-31
32. Heymans S, Pauschinger M, De Palma A, et al. Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis. Circulation 2006;114:565-73
33. Macfelda K, Weiss TW, Kaun C, et al. Plasminogen activator inhibitor 1 expression is regulated by the inflammatory mediators interleukin-1α, tumor necrosis factor-α, transforming growth factor-β and oncostatin M in human cardiac myocytes. J Mol Cell Cardiol 2002;34:1681-91